EPIX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EPIX
Portfolio Pulse from
Rosen Law Firm is pursuing a securities class action lawsuit against ESSA Pharma Inc. (EPIX) alleging the company misled investors about the efficacy of its prostate cancer drug masofaniten. The lawsuit claims the company failed to disclose that the drug combination with enzalutamide showed no clear efficacy benefit and overstated its clinical and commercial prospects. Investors who purchased EPIX securities between December 12, 2023, and October 31, 2024, are encouraged to join the class action before the March 25, 2025 deadline.
March 20, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The securities class action lawsuit could negatively impact ESSA Pharma's stock price by highlighting potential misrepresentations about its drug's efficacy and commercial prospects.
The lawsuit alleges significant misrepresentations about the company's drug development, which could erode investor confidence and potentially lead to stock price decline. The specific claims about overstated clinical and commercial prospects directly challenge the company's previous communications.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100